These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10593354)

  • 81. Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.
    Breteler MM
    BMJ; 1998 Apr; 316(7139):1182-3. PubMed ID: 9552992
    [No Abstract]   [Full Text] [Related]  

  • 82. Anti-parkinsonian drugs today.
    Quinn NP
    Drugs; 1984 Sep; 28(3):236-62. PubMed ID: 6435991
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches.
    Lang AE
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):210-20. PubMed ID: 6143611
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
    Kelm-Nelson CA; Brauer AF; Ciucci MR
    Behav Brain Res; 2016 Jul; 307():54-64. PubMed ID: 27025445
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Pharmacotherapy and guidelines].
    Baas H
    Pharm Unserer Zeit; 2006; 35(3):242-8. PubMed ID: 16724528
    [No Abstract]   [Full Text] [Related]  

  • 86. Possible applications for dopaminergic agents following traumatic brain injury: part 2.
    Zafonte RD; Lexell J; Cullen N
    J Head Trauma Rehabil; 2001 Feb; 16(1):112-6. PubMed ID: 11277855
    [No Abstract]   [Full Text] [Related]  

  • 87. [Vascular parkinsonism].
    Zhuchenko TD; Veĭn AM; Golubev VL; Shtul'man DR; Shvareva IS
    Zh Nevrol Psikhiatr Im S S Korsakova; 1998; 98(4):62-5. PubMed ID: 9606903
    [No Abstract]   [Full Text] [Related]  

  • 88. Parkinsonism from methanol poisoning: benefit from treatment with anti-Parkinson drugs.
    Davis LE; Adair JC
    Mov Disord; 1999 May; 14(3):520-2. PubMed ID: 10348484
    [No Abstract]   [Full Text] [Related]  

  • 89. Deep brain stimulation of the subthalamic nucleus for peripherally induced parkinsonism.
    Baizabal-Carvallo JF; Jankovic J
    Neuromodulation; 2014 Jan; 17(1):104-6. PubMed ID: 23663196
    [No Abstract]   [Full Text] [Related]  

  • 90. Novel use of levodopa in human immunodeficiency virus encephalopathy-mediated parkinsonism in an adult.
    Devine MF; Herrin C; Warnack W; Dubey D
    J Postgrad Med; 2018; 64(1):53-55. PubMed ID: 28862245
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Parkinsonism and bipolar affective disorder.
    Northcott C; Lunn V; Yatham LN
    Can J Psychiatry; 1995 Apr; 40(3):159-60. PubMed ID: 7606708
    [No Abstract]   [Full Text] [Related]  

  • 92. Freezing of Gait in Parkinsonism and its Potential Drug Treatment.
    Zhang LL; Canning SD; Wang XP
    Curr Neuropharmacol; 2016; 14(4):302-6. PubMed ID: 26635194
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Oculogyric-like crises in a 92-year-old woman with vascular Parkinsonism.
    Scarmeas N; Eidelberg D; Frucht SJ
    Mov Disord; 2001 Mar; 16(2):353-5. PubMed ID: 11295794
    [No Abstract]   [Full Text] [Related]  

  • 94. Levodopa-carbidopa treatment and falsely high urinary dopamine levels.
    Chandrasekaran S; Ionica N; Streeten EA
    Endocr Pract; 2013; 19(2):377-8. PubMed ID: 23738369
    [No Abstract]   [Full Text] [Related]  

  • 95. Treatment options in Parkinson's disease.
    Beizer JL
    Am Pharm; 1995 Jan; NS35(1):20-30; quiz 30-2. PubMed ID: 7887371
    [No Abstract]   [Full Text] [Related]  

  • 96. Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism.
    Giladi N; Melamed E
    Mov Disord; 1999 Jan; 14(1):158-9. PubMed ID: 9918362
    [No Abstract]   [Full Text] [Related]  

  • 97. Practical guidelines for management of Parkinson disease.
    Manyam BV
    J Am Board Fam Pract; 1997; 10(6):412-24. PubMed ID: 9407482
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Deleterious cognitive and motoric effects of haloperidol in an adolescent with cerebral palsy: a case report.
    Mortimer D; Gelfius CD; Potts MA
    PM R; 2013 Dec; 5(12):1077-80. PubMed ID: 24332231
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Hemiparkinsonism. A human model for studying dopaminergic supersensitivity.
    Trabucchi M; Albizzati MG; Frattola L; Scarlato G
    Arch Neurol; 1979 Apr; 36(4):246-8. PubMed ID: 426672
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A case of L-dopa-responsive parkinsonian syndrome after low-dose oral methotrexate intake.
    Papapetropoulos S; Argyriou AA; Liossis SN; Daousis D; Katsoulas G; Apostolopoulos D; Chroni E
    Clin Neuropharmacol; 2004; 27(2):95-8. PubMed ID: 15252273
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.